Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
9/16/2021
CDE Seeks Comments on Draft Chinese Translation of ICH Guideline E14
9/16/2021
CDE Publicizes the List of Reference Formulations for GQCE Studies (49...
9/16/2021
Takeaways from Recent Implementation of China's Patent Linkage System
9/15/2021
FiercePharma: BeiGene's Brukinsa Turns Up Heat against Imbruvica with ...
9/15/2021
The Legislative Approach and System Improvement of China's Compulsory ...
9/15/2021
Haisco to Pay $150M for China Rights of Biosplice's New Osteoarthritis...
9/15/2021
Hua Medicine and Sinopharm Enter Supply Chain Strategic Cooperation
9/15/2021
NMPA Holds the 6th China-ASEAN Summit for Drug Development and Coopera...
9/15/2021
BeiGene Granted Accelerated U.S. Approval of BRUKINSA (Zanubrutinib) i...
9/15/2021
Coherus and Junshi Biosciences Publish Results from Phase 3 Study of ...
9/15/2021
CStone Secures China NMPA IND Approval for CS2006/NM21-1480
9/15/2021
Zai Lab Granted Chinese Breakthrough Therapy Designation for Bemarituz...
9/15/2021
BeiGene Announces U.S. FDA Acceptance of BLA for Tislelizumab in ESCC
9/15/2021
Legend Biotech Begins P1 Trial in the US to Evaluate Investigational A...
9/15/2021
China to Improve Medical Insurance System in the 14th FYP to Better Me...
9/14/2021
CDE Issues the Technical Guidance for Clinical Trial of Attention Defi...
9/14/2021
CDE Issues the Technical Guidelines for Clinical Trial of Improvement ...
9/13/2021
NMPA and MOFCOM Holds Seminar to Boost Drug Regulatory Cooperation am...
9/13/2021
NHSA and NHC Issues Joint Notice to Facilitate BMI Drug Negotiation Ou...
9/13/2021
2021 Internet Hospital Report Unveils Surging Online Healthcare Resour...
9/13/2021
Everest Licesens Select Asian Rights of Providence's mRNA COVID Vaccin...
9/13/2021
Y mAbs/SciClone Granted Priorit Review of BLA for DANELZA (naxitamab-g...
9/13/2021
Hutchmed's Amdizalisib Drug Granted Breakthrough Designation by China
9/13/2021
ITM and Chengdu Gaotong Isotope Form Chinese JV for Diagnostic and The...
9/10/2021
CDE Solicits Public Comments on the Guidance Principles for Clinical T...
9/10/2021
JPO Publicizes Product and Manufacturer Information on the 6th Round o...
9/10/2021
Recent Executive Moves
9/9/2021
CDE Solicits Public Comments on the Guidance Principles for Random All...
9/9/2021
CDE Solicits Public Comments on the Guiding Principles for Comprehensi...
9/9/2021
China's Personal Info Protection Law Has Significant Implications for ...
Page:
114
/
719
Total number of articles:
21549
:
[First]
[<<]
[112]
[113]
[114]
[115]
[116]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit